The Europe Liver Disease Diagnostics Market would witness market growth of 6.1% CAGR during the forecast period (2020-2026).
Growing incidences of obesity, metabolic syndrome, diabetes, and cardiovascular diseases that contribute to liver disease are another significant factor that fuels the growth of the liver disease treatment market. In addition, an increase in the incidence of liver disease due to the side effects of other medications such as acetaminophen and poor hygienic and sanitation conditions is projected to drive the demand in the coming years.
Liver disease in the United Kingdom has increased dramatically, particularly in people under 65 years of age — a marked contrast to all other major causes of death that have decreased in younger age groups. The epidemic was caused by alcohol, obesity and hepatitis C. LFTs are usually abnormal due to a number of causes, such as drinking too much, fatty liver due to obesity, infections, rare liver diseases, and certain cancers — but they may be a symptom of potentially fatal liver disease.
The liver is the body’s factory, producing vital proteins and breaking down or excreting waste products. Liver disease is usually a silent illness in its early stages. Liver function tests (LFTs) are commonly available blood tests associated with liver damage, so early detection of liver diseases would be possible. Millions of these tests are carried out every year in the United Kingdom by doctors and nurses for a variety of symptoms and conditions ranging from tiredness, yellowing of the skin (in white people) to the whiteness of the eyes due to jaundice.
Based on End User, the market is segmented into Hospitals, Laboratories and Other End Users. Based on Diagnosis Technique, the market is segmented into Imaging, Biopsy, Endoscopy, Laboratory tests and Other Diagnosis Techniques. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Boston Scientific Corporation, Siemens AG (Siemens Healthineers), Bayer AG, Merck & Co., Inc., Sanofi S.A., Novartis AG, Pfizer, Inc., and Randox laboratories limited
Scope of the Study
By End User
• Hospitals, Laboratories and Other End Users
By Diagnosis Technique
• Laboratory tests and
• Other Diagnosis Techniques
• Rest of Europe
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Boston Scientific Corporation
• Siemens AG (Siemens Healthineers)
• Bayer AG
• Merck & Co., Inc.
• Sanofi S.A.
• Novartis AG
• Pfizer, Inc.
• Randox laboratories limited
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Our reports have been used by over 10K customers, including:
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
17 pages •
By Euromonitor International
• Dec 2020
Positive net migration will be the main driver of UK population growth in 2019-2040. Ageing will be a key demographic trend over this time, transforming consumer trends and putting further pressure on state resources. Immigrants will make up over a tenth of the UK population by 2040, with those from Poland and India continuing to make up the...
Summary Protagen AG (Protagen) is a medical device company that develops molecular diagnostic and companion diagnostic test equipment.The company’s products include multilisa SSC, multilisa SLE and multilisa RA. It provides products for autoimmune diseases such as rheumatoid arthritis, neuromyelitis optica, systemic...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Neurovascular Devices Market by Product (Embolization Devices, Revascularization Devices, Embolic Protection Devices, and Accessory Devices), Disease Pathology (Aneurysm, Arteriovenous Malformation (AVM), Ischemic Stroke, Stenosis, and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
Peripheral Vascular Device
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.